Justia Products Liability Opinion Summaries

The case involves the plaintiffs, including the estate of Carson Bride and three minors, who suffered severe harassment and bullying through the YOLO app, leading to emotional distress and, in Carson Bride's case, suicide. YOLO Technologies developed an anonymous messaging app that promised to unmask and ban users who engaged in bullying or harassment but allegedly failed to do so. The plaintiffs filed a class action lawsuit against YOLO, claiming violations of state tort and product liability laws.The United States District Court for the Central District of California dismissed the plaintiffs' complaint, holding that Section 230 of the Communications Decency Act (CDA) immunized YOLO from liability. The court found that the claims sought to hold YOLO responsible for third-party content posted on its app, which is protected under the CDA.The United States Court of Appeals for the Ninth Circuit reviewed the case. The court reversed the district court's dismissal of the plaintiffs' misrepresentation claims, holding that these claims were based on YOLO's promise to unmask and ban abusive users, not on a failure to moderate content. The court found that the misrepresentation claims were analogous to a breach of promise, which is not protected by Section 230. However, the court affirmed the dismissal of the plaintiffs' product liability claims, holding that Section 230 precludes liability because these claims attempted to hold YOLO responsible as a publisher of third-party content. The court concluded that the product liability claims were essentially about the failure to moderate content, which is protected under the CDA. View "Estate of Bride v. Yolo Technologies, Inc." on Justia Law

Hardin suffered complete blindness and permanent, severe and painful scarring after she took Lamotrigine, the generic form of the medication Lamictal. Hardin sued the prescribing physician, the manufacturer, the store where she bought the prescription (Safeway), WKH, which produced the drug information pamphlet (monograph), and PDX, a software provider that distributes drug information to pharmacy customers. Unlike physician package inserts and patient medication guides, which are FDA-mandated, WKH monographs are not regulated or reviewed by the FDA, but are produced as part of a self-regulating action plan required under 110 Stat. 1593. The WKH monograph was the only information received by Hardin when she first filled her prescription for Lamictal. The abbreviated warning used by Safeway and provided to Hardin omitted the “Black Box” warning: “BEFORE USING THIS MEDICINE” that stated: “SERIOUS AND SOMETIMES FATAL RASHES HAVE OCCURRED RARELY WITH THE USE OF THIS MEDICINE. Hardin says that had she been provided this warning, she would not have taken the medication. WKH moved to strike Hardin’s claims against it under Code of Civil Procedure section 425.16, the “anti-SLAPP” (Strategic Lawsuit Against Public Participation ) statute.. The trial court ruled that WKH’s production of drug monographs was protected speech concerning a public issue or an issue of public interest and that Hardin had no probability of prevailing because she could not establish that WKH owed her any duty. The court denied PDX’s motion to strike, finding that the activity underlying PDX’s alleged liability was the reprogramming of its software to permit Safeway to give customers an abbreviated, five-section monograph that omitted warnings instead of the full eight-section version that included those warnings. The court of appeal affirmed. View "Hardin v. PDX, Inc." on Justia Law